{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-066821","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2026-06-09T20:30:15+00:00","discovered_at":"2026-06-09T20:31:00.220143+00:00","generated_at":"2026-06-09T20:32:20.464273+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"MoonLake shareholders approve 5M share increase to equity plan at 2026 AGM","bullets":["Shareholders approved amendment to 2022 Equity Incentive Plan, adding 5,000,000 Class A shares for awards.","Plan now includes one-year minimum vesting requirement, revised director compensation limits, and term through 2036.","Director Spike Loy re-elected with 92.4% of votes cast; auditor Baker Tilly ratified with 99.9% support.","Advisory vote on executive compensation passed with 98.6% of votes cast in favor.","Total shares authorized under the plan now 9,353,948, subject to adjustment provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-066821","json":"https://secwatch.observer/filing/0001213900-26-066821.json","markdown":"https://secwatch.observer/filing/0001213900-26-066821.md","text":"https://secwatch.observer/filing/0001213900-26-066821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/ea0294064-8k_moonlake.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T20:32:20.464273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14153b14335e8d6d14d6acc280e08be966d3509b","claim":"MoonLake Immunotherapeutics shareholders approved Election of Class I Director Nominee.","evidence_excerpt":"At the Annual Meeting, the Class I director nominee was elected and the other proposals voted on were approved. The final voting results are set forth below: Votes For Votes Withheld Broker Non-Votes Proposal 1. Election of the Class I Director Nominee ● Spike Loy 47,222,233 3,889,131 10,761,142","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"62e351b2c3f792005eed1f93e4c45d03f9f7cd85","claim":"MoonLake Immunotherapeutics shareholders approved Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan.","evidence_excerpt":"Proposal 4. Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan 50,599,032 498,186 14,146 10,761,142","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"ace6c64643f02ceb593bb5083a2488d20c2fdcb8","claim":"MoonLake Immunotherapeutics shareholders approved Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor.","evidence_excerpt":"Proposal 2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor 61,831,463 17,522 23,521 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"af4442cf207d8c5729cabba47e173e6eb6fe00ec","claim":"MoonLake Immunotherapeutics shareholders approved Advisory Vote on Executive Compensation.","evidence_excerpt":"Proposal 3. Advisory Vote on Executive Compensation 50,365,168 731,158 15,038 10,761,142","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}